Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: an antineoplastic agent.

Robert J Amato1

  • 1Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA. ramato@bcm.tmc.edu

Current Oncology Reports
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues.

Frontiers in molecular biosciences·2019
Same author

Klotho inhibits EGF-induced cell migration in Caki-1 cells through inactivation of EGFR and p38 MAPK signaling pathways.

Oncotarget·2018
Same author

CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.

Oncotarget·2014
Same author

Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4.

The International journal of biological markers·2014
Same author

Folate receptor-β constitutes a marker for human proinflammatory monocytes.

Journal of leukocyte biology·2014
Same author

A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2014

Thalidomide, once withdrawn, shows promise for immune dysregulation and inflammation. Its immunomodulatory, anti-inflammatory, and anti-angiogenic effects are being explored for various conditions, including dermatologic disorders and cancers.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Thalidomide, withdrawn decades ago, is regaining interest for its immunomodulatory and anti-inflammatory properties.
  • It reduces tumor necrosis factor-alpha activity and inhibits angiogenesis.
  • Approved for erythema nodosum leprosum, its use is expanding to other immune-related dermatologic and HIV-associated conditions.

Purpose of the Study:

  • To review the expanding applications of thalidomide.
  • To highlight its immunomodulatory, anti-inflammatory, and anti-angiogenic mechanisms.
  • To explore its potential in oncology for solid tumors and hematologic malignancies.

Main Methods:

  • Literature review of studies on thalidomide's effects.
  • Analysis of clinical evidence for dermatologic disorders, HIV infection, and cancer.

Related Experiment Videos

  • Examination of its molecular mechanisms, including cytokine degradation and angiogenesis inhibition.

    • Main Results:

    • Thalidomide effectively treats erythema nodosum leprosum, aphthous stomatitis, Behcet's syndrome, lupus erythematosus, and graft-versus-host disease.
    • It shows efficacy in managing oral ulcers, wasting syndrome, diarrhea, and Kaposi's sarcoma in HIV patients.
    • Emerging research demonstrates its anti-angiogenic and immunomodulatory potential in various cancers.

    Conclusions:

    • Thalidomide is a versatile therapeutic agent with significant potential in immune-related disorders.
    • Its anti-inflammatory and anti-angiogenic properties warrant further investigation in oncology.
    • Thalidomide represents a valuable option for managing complex inflammatory and neoplastic conditions.